About

About Beijing InnoModels Biotechnologies Founded in 2020, Beijing InnoModels Biotechnologies is a preclinical CRO specializing in oncology and immuno-oncology research. The company provides comprehensive in vivo and in vitro pharmacology services, including molecular and cellular biology, PDO, CDX, PDX, and syngeneic tumor models, humanized mouse models, PK/PD studies, flow cytometry, in vivo imaging, and non-GLP toxicology. InnoModels has supported over 600 partners across more than 2,000 projects, offering integrated platforms that bridge the gap between preclinical and clinical development. Its advanced humanized immune system and PDX model platforms enable efficient evaluation of immunotherapies and early assessment of clinical value. Backed by an experienced scientific team, InnoModels is committed to accelerating drug development through innovative and reliable preclinical solutions.